Theralink Technologies, Inc. (OBMP) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Theralink Technologies, Inc. (OBMP) trades at $1.56. Theralink Technologies, Inc. is a commercial-stage precision medicine company focused on developing and commercializing cancer immunotherapy products. Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Mar 16, 2026Analyst Coverage for OBMP: OBMP does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates OBMP against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
OBMP: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bullish.
How is this calculated? →Theralink Technologies, Inc. (OBMP) Healthcare & Pipeline Overview
Theralink Technologies, Inc. (OBMP) is a precision medicine company leveraging its patented biomarker platform to provide data-driven insights for cancer treatment. Targeting the biopharmaceutical industry and clinical oncologists, Theralink's assays aim to identify patient responses to cancer therapies, operating in the competitive biotechnology sector.
What Is the Investment Thesis for OBMP?
Theralink Technologies operates in the growing precision medicine market, offering potential for revenue growth through its proprietary biomarker platform. The company's ability to provide data-driven insights into cancer treatment response could drive adoption by biopharmaceutical companies and clinical oncologists. However, the company's negative P/E ratio of -1497.76 and a high beta of 26.28 indicate significant financial risk and volatility. A key value driver is the expansion of its assay offerings and partnerships with pharmaceutical companies. The ongoing development of novel cancer immunotherapy products represents a potential catalyst. Investors should carefully consider the risks associated with OTC trading and the company's financial performance.
Based on FMP financials and quantitative analysis
OBMP Key Highlights
Theralink Technologies operates with a small team of 16 employees, indicating a lean operational structure.
- The company's gross margin stands at 76.8%, suggesting strong pricing power and efficient cost management in its assay services.
- Theralink's P/E ratio is -1497.76, reflecting current unprofitability.
- The company's profit margin is -1106.2%, indicating significant expenses relative to revenue.
- Theralink operates in the biotechnology industry, focusing on precision medicine and molecular data generation.
Who Are OBMP's Competitors?
OBMP is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ABCZF Abcam plc | $22.25 | +0.68% | $5.12B | 46 |
| ASPHF Ascentage Pharma Group International | $4.53 | +0.00% | $1.69B | 51 |
| DCHPF Dechra Pharmaceuticals PLC | $46.90 | -0.21% | $5.34B | 48 |
| DPHAY Dechra Pharmaceuticals PLC | $98.00 | +1.98% | $6.00B | 48 |
| HNGZY Hangzhou Tigermed Consulting Co., Ltd. | $4.45 | +0.00% | $6.86B | 45 |
| VRTX Vertex Pharmaceuticals Incorporated | $540.26 | -2.14% | $137B | 98 |
| REGN Regeneron Pharmaceuticals, Inc. | $835.15 | -0.68% | $86.0B | 94 |
| ALNY Alnylam Pharmaceuticals, Inc. | $229.30 | -5.49% | $30.7B | 92 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are OBMP's Key Strengths?
Proprietary biomarker platform.
- Focus on precision oncology.
- Potential for personalized cancer treatment.
- Commercial-stage company with revenue generation.
What Are OBMP's Weaknesses?
Negative P/E ratio and profit margin.
- High beta indicating volatility.
- Small number of employees.
- OTC market listing.
What Could Drive OBMP Stock Higher?
Publication of clinical trial results using Theralink's assays (timeline: next 6-12 months).
- Potential FDA approval of a drug utilizing Theralink's companion diagnostic (timeline: next 12-24 months).
- Expansion of partnerships with biopharmaceutical companies for drug development.
- Increasing adoption of Theralink's assays by clinical oncologists.
- Development of new Reverse Phase Protein Array (RPPA) assays targeting additional cancer types.
What Are the Key Risks for OBMP?
Competition from larger biotechnology companies with greater resources.
- Regulatory hurdles for new assays and diagnostics.
- Dependence on biopharmaceutical partnerships for revenue generation.
- Risk of technological obsolescence in the rapidly evolving field of precision medicine.
- Financial instability due to negative P/E ratio and profit margin.
What Are the Growth Opportunities for OBMP?
- Expansion of Assay Portfolio: Theralink can expand its revenue streams by developing and commercializing new Reverse Phase Protein Array (RPPA) assays targeting additional cancer types and drug targets. The market for precision oncology diagnostics is projected to reach $88 billion by 2030, offering a substantial opportunity for growth. The timeline for developing and validating new assays is typically 12-18 months, with commercialization following regulatory approval or validation. This expansion could attract more biopharmaceutical partnerships and increase clinical adoption.
- Strategic Partnerships with Biopharmaceutical Companies: Theralink can leverage its proprietary biomarker platform to establish strategic partnerships with biopharmaceutical companies for drug development and clinical trials. These partnerships can provide upfront payments, milestone payments, and royalties on future sales of drugs developed using Theralink's data. The market for drug development collaborations is estimated at $40 billion annually. Securing multiple partnerships within the next 2-3 years could significantly boost Theralink's revenue and validation.
- Geographic Expansion: Theralink can expand its geographic reach by offering its assays and services in international markets, such as Europe and Asia. The global market for precision medicine is growing rapidly, with significant opportunities in countries with advanced healthcare systems and increasing cancer incidence. Entering new markets typically requires regulatory approvals and establishing local partnerships, with a timeline of 18-24 months. This expansion could diversify Theralink's revenue base and reduce its reliance on the US market.
- Data Licensing and Analytics Services: Theralink can generate additional revenue by licensing its proprietary biomarker data to biopharmaceutical companies and offering data analytics services. This data can be used for drug discovery, target validation, and patient stratification. The market for healthcare data analytics is projected to reach $68 billion by 2028. Developing a robust data licensing and analytics platform within the next year could create a recurring revenue stream and enhance Theralink's competitive advantage.
- Development of Companion Diagnostics: Theralink can pursue the development of companion diagnostics to identify patients who are most likely to benefit from specific cancer therapies. Companion diagnostics are often required for the approval and reimbursement of targeted therapies, creating a significant market opportunity. The market for companion diagnostics is projected to reach $12 billion by 2027. Developing and commercializing companion diagnostics within the next 3-5 years could significantly increase Theralink's revenue and market share.
What Are OBMP's Competitive Advantages?
- Patented phosphoprotein and protein biomarker platform.
- Proprietary Theralink Reverse Phase Protein Array assays.
- Expertise in precision oncology and molecular data generation.
- Established relationships with biopharmaceutical companies.
What Does OBMP Do?
Theralink Technologies, Inc., formerly known as OncBioMune Pharmaceuticals, Inc., rebranded in September 2020 to reflect its focus on precision medicine. The company is dedicated to the development and commercialization of cancer immunotherapy products. Headquartered in Golden, Colorado, Theralink operates as a commercial-stage molecular data-generating company. Its core technology revolves around a patented phosphoprotein and protein biomarker platform, which is used in laboratory-developed test technology. Theralink's primary offering is precision oncology data generated through its Theralink Reverse Phase Protein Array assays. These assays provide actionable information to assist biopharmaceutical companies and clinical oncologists in determining which patients are likely to respond or not respond to specific FDA-approved and investigational drug treatments. By providing this data, Theralink aims to improve treatment outcomes and personalize cancer therapy. The company's assays target multiple areas of oncology and drug development, positioning it as a key player in the evolving field of precision medicine.
What Products and Services Does OBMP Offer?
- Develop and commercialize novel cancer immunotherapy products.
- Utilize a patented phosphoprotein and protein biomarker platform.
- Provide precision oncology data through Theralink Reverse Phase Protein Array assays.
- Assist biopharmaceutical companies in identifying likely responders and non-responders to cancer treatments.
- Offer data-generating assays that provide actionable information for physicians and patients.
- Target multiple areas of oncology and drug development.
How Does OBMP Make Money?
- Generate revenue through the sale of Theralink Reverse Phase Protein Array assays.
- Partner with biopharmaceutical companies for drug development and clinical trials.
- Provide data analytics services to biopharmaceutical companies.
- Potentially develop and commercialize companion diagnostics.
What Industry Does OBMP Operate In?
Theralink Technologies operates within the biotechnology industry, specifically in the precision medicine segment. This market is characterized by rapid innovation, increasing demand for personalized therapies, and stringent regulatory requirements. The competitive landscape includes companies developing diagnostic tools and targeted therapies. Theralink's focus on phosphoprotein and protein biomarker analysis positions it to capitalize on the trend toward data-driven cancer treatment decisions. The biotechnology industry is experiencing growth driven by advances in genomics, proteomics, and immunotherapy, with significant investment in research and development.
Who Are OBMP's Key Customers?
- Biopharmaceutical companies developing cancer therapies.
- Clinical oncologists treating cancer patients.
- Hospitals and cancer centers.
- Research institutions conducting cancer research.
Company Profile
Theralink Technologies, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Golden, US. OBMP has traded publicly since 2021.
Key Financial Metrics
Return on equity for Theralink Technologies, Inc. stands at 147.5%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.03 means current liabilities exceed short-term assets, a liquidity point worth watching.
Insider Activity
The most recent 9 insider filings for Theralink Technologies, Inc. break down as 3 sales and 6 purchases. On net that is roughly 11.2M shares acquired (about $138K) — insiders putting money in tends to read as conviction.
OBMP Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Proprietary biomarker platform.
- Focus on precision oncology.
- Potential for personalized cancer treatment.
- Commercial-stage company with revenue generation.
Bear Case
- Negative P/E ratio and profit margin.
- High beta indicating volatility.
- Small number of employees.
- OTC market listing.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
OBMP Latest News
No recent news available for OBMP.
OBMP Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for OBMP.
Price Targets
Wall Street price target analysis for OBMP.
OBMP MoonshotScore
What does this score mean?
The MoonshotScore rates OBMP 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
OBMP OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that Theralink Technologies may not meet the minimum financial standards or reporting requirements of higher tiers like OTCQX or OTCQB. Companies in this tier may have limited financial disclosure and may not be subject to the same level of regulatory oversight as companies listed on major exchanges like the NYSE or NASDAQ. This tier often includes companies with higher risk profiles and speculative ventures.
- OTC Tier: OTC Other
- Limited financial disclosure due to OTC Other tier status.
- Thin trading volume and potential for price manipulation.
- Higher risk of fraud or mismanagement compared to listed companies.
- Limited regulatory oversight and investor protection.
- Potential for delisting or trading suspension.
- Verify the company's financial statements and SEC filings (if any).
- Research the background and experience of the company's management team.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's legal and regulatory compliance.
- Monitor news and press releases for any red flags.
- Consult with a qualified financial advisor before investing.
- Commercial-stage company with revenue generation.
- Patented biomarker platform and proprietary assays.
- Focus on precision oncology and data-driven insights.
- Partnerships with biopharmaceutical companies (if any).
OBMP Healthcare Stock FAQ
What does Theralink Technologies, Inc. do?
Theralink Technologies, Inc. is a precision medicine company focused on improving cancer treatment outcomes through its patented biomarker platform. The company develops and commercializes Reverse Phase Protein Array (RPPA) assays that provide actionable data to biopharmaceutical companies and clinical oncologists. These assays help identify patients who are likely to respond or not respond to specific cancer therapies, enabling personalized treatment decisions and potentially improving drug development efficiency.
What are the key revenue streams for Theralink Technologies, Inc.?
Theralink Technologies, Inc. generates revenue primarily through the sale of its Theralink Reverse Phase Protein Array (RPPA) assays to biopharmaceutical companies and clinical oncologists. These assays are used in drug development, clinical trials, and patient treatment decisions.
What are the main risks for OBMP?
Theralink Technologies, Inc. faces several key risks, including intense competition from larger biotechnology companies with greater resources, regulatory hurdles for new assays and diagnostics, dependence on biopharmaceutical partnerships for revenue, and the risk of technological obsolescence in the rapidly evolving field of precision medicine. Additionally, the company's negative P/E ratio and profit margin indicate financial instability and reliance on external funding, which could dilute shareholder value.
How does Theralink Technologies, Inc. navigate regulatory approval processes?
Theralink Technologies, Inc. operates in a highly regulated environment and must comply with FDA regulations for its assays and diagnostics. The company typically follows a rigorous validation process for its laboratory-developed tests (LDTs) and may pursue FDA approval for companion diagnostics.
What are the potential benefits of using Theralink Technologies, Inc.'s assays in cancer treatment?
Theralink Technologies, Inc.'s assays offer several potential benefits in cancer treatment, including improved patient selection for targeted therapies, enhanced drug development efficiency, and reduced healthcare costs. By identifying patients who are most likely to respond to specific treatments, these assays can help oncologists make more informed decisions and avoid prescribing ineffective therapies.
What are the key factors to evaluate for OBMP?
Evaluate OBMP on fundamentals, analyst consensus, and risk factors. Theralink Technologies operates in the growing precision medicine market, offering potential for revenue growth through its proprietary biomarker platform. Not financial advice.
How frequently does OBMP data refresh on this page?
OBMP's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven OBMP's recent stock price performance?
Theralink Technologies, Inc. (OBMP) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Proprietary biomarker platform. See the News tab for the latest drivers. Past performance does not predict future results.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- OTC data may be less reliable than exchange-listed data.
- AI analysis is pending and may provide further insights.